menu
    • menu
    [{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"NTC","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"ITALY","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Levofloxacin","moa":"DNA gyrase","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Taro Pharmaceutical Industries \/ Taro Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Taro Pharmaceutical Industries \/ Taro Pharmaceutical"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Crescita Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Taro Pharmaceutical Industries \/ Taro Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Taro Pharmaceutical Industries \/ Taro Pharmaceuticals"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Deferiprone","moa":"Iron","graph1":"Genetic Disease","graph2":"Approved","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Taro Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Taro Pharmaceutical Industries \/ Not Applicable"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Alchemee","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Benzoyl Peroxide","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Taro Pharmaceutical Industries \/ Taro Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Taro Pharmaceutical Industries \/ Taro Pharmaceutical"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Galderma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Benzoyl Peroxide","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Taro Pharmaceutical Industries","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0.10000000000000001,"dosageForm":"Topical Solution","sponsorNew":"Taro Pharmaceutical Industries \/ Taro Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Taro Pharmaceutical Industries \/ Taro Pharmaceutical"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Intellipharmaceutics Corporation","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Desvenlafaxine Succinate","moa":"SNRI","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Taro Pharmaceutical Industries \/ Intellipharmaceutics","highestDevelopmentStatusID":"12","companyTruncated":"Taro Pharmaceutical Industries \/ Intellipharmaceutics"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Merger","leadProduct":"Acetazolamide","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Taro Pharmaceutical Industries \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"12","companyTruncated":"Taro Pharmaceutical Industries \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Merger","leadProduct":"Acetazolamide","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Taro Pharmaceutical Industries \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"12","companyTruncated":"Taro Pharmaceutical Industries \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Merger","leadProduct":"Acetazolamide","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Taro Pharmaceutical Industries \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"12","companyTruncated":"Taro Pharmaceutical Industries \/ Sun Pharmaceutical Industries Limited"}]

    Find Clinical Drug Pipeline Developments & Deals by Taro Pharmaceutical Industries

    Menu

    Taro Pharmaceutical Industries

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Taro Pharmaceutical Industries

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Taro Pharmaceutical Industries

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Acetazolamide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Sponsor : Sun Pharmaceutical Industries Limited

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Sun Pharma Completes Taro Merger

                            Details : Sun Pharma will gain access to Taro's pipelines, including Diamox (acetazolamide), an carbonic anhydrase inhibitor used for treating edema due to congestive heart failure in patients.

                            Brand Name : Diamox

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 24, 2024

                            Lead Product(s) : Acetazolamide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Sponsor : Sun Pharmaceutical Industries Limited

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Taro Pharmaceutical Industries

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Taro Pharmaceutical Industries

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Acetazolamide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Sponsor : Sun Pharmaceutical Industries Limited

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Taro Shareholders Approve Merger with Sun Pharma

                            Details : Sun Pharma will gain access to Taro's pipelines, including Diamox (acetazolamide), an carbonic anhydrase inhibitor used for treating edema due to congestive heart failure in patients.

                            Brand Name : Diamox

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 23, 2024

                            Lead Product(s) : Acetazolamide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Sponsor : Sun Pharmaceutical Industries Limited

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Taro Pharmaceutical Industries

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Taro Pharmaceutical Industries

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Acetazolamide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Sponsor : Sun Pharmaceutical Industries Limited

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Taro Announces Merger Agreement with Sun Pharma

                            Details : Through the merger, Sun Pharma will gain access to Taro's pipelines, including Diamox (acetazolamide), a carbonic anhydrase inhibitor for treating edema due to congestive heart failure.

                            Brand Name : Diamox

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 17, 2024

                            Lead Product(s) : Acetazolamide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Sponsor : Sun Pharmaceutical Industries Limited

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Taro Pharmaceutical Industries

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Taro Pharmaceutical Industries

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Desvenlafaxine Succinate

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved

                            Sponsor : Intellipharmaceutics Corporation

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Intellipharmaceutics Signs an Exclusive License & Supply Agreement with Taro Pharmaceuticals Inc. for Desvenla...

                            Details : Company has granted Taro an exclusive license to market, sell and distribute in Canada, Desvenlafaxine Extended-release Tablets in the 50 mg and 100 mg strengths approved for sale in the Canadian market by the Pharmaceutical Drugs Directory (PDD) of Heal...

                            Brand Name : Desvenlafaxine-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 16, 2022

                            Lead Product(s) : Desvenlafaxine Succinate

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved

                            Sponsor : Intellipharmaceutics Corporation

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Taro Pharmaceutical Industries

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Taro Pharmaceutical Industries

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Benzoyl Peroxide

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Recipient : Galderma

                            Deal Size : $99.3 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Sun Pharma's US subsidiary acquires Galderma's companies in US, Japan & Canada

                            Details : Taro Pharmaceutical Industries, has agreed to acquire all of the outstanding capital stock of Galderma ; Proactiv YK ; The Proactiv Company ; used in the business of developing, manufacturing, marketing, selling and distributing products sold under the P...

                            Brand Name : Proactiv

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 09, 2022

                            Lead Product(s) : Benzoyl Peroxide

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Recipient : Galderma

                            Deal Size : $99.3 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Taro Pharmaceutical Industries

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Taro Pharmaceutical Industries

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Benzoyl Peroxide

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Recipient : Alchemee

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Taro Completes Acquisition of Alchemee

                            Details : The acquisition includes Alchemee’s business and assets worldwide, including the Proactiv® brand. Alchemee's flagship brand, Proactiv, is America’s 1 acne routine and has been used and trusted by millions around the world for more than 25 years.

                            Brand Name : Proactiv

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 28, 2022

                            Lead Product(s) : Benzoyl Peroxide

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Recipient : Alchemee

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Taro Pharmaceutical Industries

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Taro Pharmaceutical Industries

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Deferiprone

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Taro Pharmaceutical Launches Generic Deferiprone in U.S

                            Details : Deferiprone is an iron chelator indicated for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate. Deferiprone is the generic version of Ferriprox®.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 28, 2020

                            Lead Product(s) : Deferiprone

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Taro Pharmaceutical Industries

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Taro Pharmaceutical Industries

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lidocaine,Tetracaine

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Recipient : Crescita Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Crescita to Receive One-time Cash Payment Following Amendment to Pliaglis® U.S. Licensing Agreement

                            Details : The Company continues to pursue out-licensing partnerships with focus on approximately 20 countries where Pliaglis has already received regulatory approval.

                            Brand Name : Pliaglis

                            Molecule Type : Small molecule

                            Upfront Cash : $3.9 million

                            July 28, 2020

                            Lead Product(s) : Lidocaine,Tetracaine

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Recipient : Crescita Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Taro Pharmaceutical Industries

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Taro Pharmaceutical Industries

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Levofloxacin,Dexamethasone

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Recipient : NTC

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            NTC Grants License and Distribution Rights in Israel to Taro Pharmaceutical Industries

                            Details : NTC Srl has granted exclusive license and distribution rights to one of its R&D products to Taro Pharmaceutical. The product combines a quinolone antibiotic with an anti-inflammatory steroid in eye drops intended to provide an appropriate treatment for p...

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 17, 2020

                            Lead Product(s) : Levofloxacin,Dexamethasone

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Recipient : NTC

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth